At the opening press conference of the ESMO Congress 2021, President Solange Peters announced that ESMO, the leading professional society for medical oncology, is launching the International Cancer Foundation, ICF by its acronym, which has taken upon itself a mission to support activities that enhance cancer prevention, diagnosis, treatment and follow-up in every country where they are needed, with the ultimate goal of saving lives by ensuring that the best treatment is available to every cancer patient worldwide.
“Immunotherapy is being shown to work across many diseases and new drugs are on the horizon in the precision oncology field, but as an international organisation, we at ESMO have to be realistic about how accessible these breakthroughs are from a global perspective. Even if we constantly offered education to our members to be at the forefront of cancer research and treatment, we would still be leaving some patients at the side of the road,” said Peters, detailing that the new foundation will provide practical support for the training of oncologists as well as offer financial backing for fellowships, country-specific research projects, patient resources, prevention campaigns and public education about cancer in under-resourced regions across Africa, Asia and Latin America.
The announcement comes in the context of the ESMO Congress which, one week before its official opening, is already counting more than 19,000 participants from all around the world.
“Connecting and engaging those who care about cancer” is the fitting tagline for this second consecutive virtual edition of the highly anticipated annual event, an appointment not to be missed for the entire oncology community – and the second to be held against the backdrop of the COVID-19 pandemic.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus.
“The pandemic generated remarkable consequences on people and healthcare systems, but also on cancer research,” said ESMO Press Officer Dr. Antonio Passaro.
“This year, however, we have seen a resurrection of oncology research reflected by an increase in the number of abstracts and practice-changing data submitted, and ultimately translating to more than 2,000 studies, with nearly 70 late-breaking abstracts being presented at this ESMO Congress.”
“In addition to research, the pandemic has also disrupted the treatment strategies in place for our patients,” Passaro continued. “In this area, too, new data shows that the oncology community has worked and continues to work in the right direction to protect cancer patients during the health crisis.”
A study to be presented at the upcoming Congress explored the prevalence of long-term side-effects from COVID-19 among cancer patients having survived an infection with the virus, as well as the impact on pathways to resuming treatment following recovery.
Based on data collected about 2,795 patients at 35 European institutions between February 2020 and February 2021 through the OnCOVID registry, 1,557 patients who underwent a clinical reassessment after recovering from COVID-19 were included in the analysis.
The results show that at least 15% of cancer patients who survived an infection with SarS-CoV-2 went on to experience symptomatic sequelae from the disease, the most common being respiratory symptoms (50%), such as shortness of breath or a chronic cough, as well as chronic fatigue (41%). Men were significantly more likely than women to be burdened by sequelae, as were individuals aged over 65 years, those with two comorbidities or more and those with a history of smoking.
“The fact that the cancer patients who most frequently suffered sequelae were those who survived severe forms of the disease leads us to imagine the beneficial effects that COVID-19 vaccination campaigns will have on these aspects,” said study author Dr. Alessio Cortellini, Hammersmith Hospital and Imperial College London, UK.
Cortellini added that prevention, early recognition and treatment of COVID-19 sequelae would be an important step to prevent disruptions in the continuity of patients’ cancer care in the future.
“This data confirms the need to continue to prioritise cancer patients, which is one of the top goals that ESMO has set since the start of the outbreak,” Passaro emphasised.
“Amid the efforts invested by healthcare systems in the fight against the pandemic, it is of the utmost importance that we do not neglect to study and understand the curves of cancer incidence and mortality in order to plan appropriate health policies for the future.”
These are described in a second study, which used the latest estimates of the cancer burden in EU and EFTA countries along with the most recent projected population figures released by Eurostat for the coming decades to predict long-term cancer incidence and mortality across Europe by age, sex, country and cancer site.
The results show that by 2040, the number of new cancer cases could increase by more than a fifth (21%) to 3.4 million, with deaths from cancer reaching 1.7 million the same year, up from 1.3 million in 2020.
“We evaluated how demographic variations in terms of fertility, mortality and migration levels would impact the population age pyramid over time and how that, in turn, would affect the number of future cancer cases in 2040,” said study author Dr. Manola Bettio from the European Commission, Join Research Centre, Italy.
“The results we obtained allow international comparisons, highlighting differences and identifying possible actions to mitigate inequalities between and within countries. The first and easiest way to reduce the future cancer burden across Europe is prevention, because the good news is that almost 40% of cancers can be prevented by reducing people’s exposure to environmental and lifestyle risks, which are also linked to social and economic development.”
For those who do have to face a diagnosis of cancer, today or in the future, ESMO2021 Scientific Co-Chair Prof. Pasi Jänne saw hope in the results to be unveiled over the five days of the ESMO Congress, which are evidence that cancer research works.
“Many of the studies presented this year will change or influence our current clinical practice,” he said, highlighting great strides made in precision medicine: “Giving the right treatment at the right time, to the right patient, is an important strategy that we as an oncology community are implementing worldwide to continue making progress in cancer therapies and thus improve outcomes for patients,” Jänne said.
Watch our video interview on this study here.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.